Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Image of bacteriophage viruses

OSPT, short for Oxford Silk Phage Technologies, is developing a new material integrating bacteriophage viruses to produce medical implants reducing surgical site infections and the need for antibiotics. INCATE has selected the company to receive stage 1 funding which includes coaching and sponsored services up to €10,000.


INCATE brings together translational and basic research, industry, experienced entrepreneurs and investors from across Europe to accelerate innovation. It does this by providing advice, community and funding. The company focuses on developing new therapies, diagnostics and interventions that help reduce the prevalence and impact of Antimicrobial Resistance (AMR).


OSPT and the five other chosen ventures reflect the breadth of innovation INCATE is seeing in applications with small molecules, RNA and Phages all present. They will get a chance, along with other already selected companies, to apply for Stage II funding at INCATE with up to €250k later this year.



We look forward to meeting fellow companies/groups fighting AMR as part of INCATEurope's many networking opportunities.

Oxford Silk Phage Technologies